AGP Executive Report
Last update: 7 hours agoDrug Safety: Sun Pharma has been ordered to halt production of an eye medicine at its Assam plant after quality lapses; the company says it is taking remedial action following a voluntary withdrawal of 11 eye drops. The Supreme Court has also questioned the Centre and drug regulator over emergency approvals for expired liposomal amphotericin B. Health Technology: Omron has begun full-scale production at its first Indian factory near Chennai, aiming to make up to 3 million blood-pressure monitors a year as it targets wider home monitoring. Cancer Care: India recorded more than 200,000 new breast cancer cases in 2024, the Health Secretary said, urging early screening; authorities have also cut prices of some cancer medicines by up to 93%, though many listed drugs saw no reduction. Access to Care: GMC Handwara has installed north Kashmir’s first government MRI machine, while Maharashtra hospitals will offer eligible patients free PET-CT, MRI and CT scans. Air Pollution: Delhi-NCR will restrict construction and cap office attendance from November 5 as winter pollution risks rise.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
